Correlation of Survival and Other Clinical Benefits With Imetelstat Therapy in High-Risk, JAK Inhibitor–Refractory Myelofibrosis

Downloadable summary slideset from a live webinar on treatment approaches for lower-risk, higher-risk, and relapsed/refractory MDS, from Clinical Care Options (CCO)

Michael J. Savona, MD
Program Director Jacqueline S. Garcia, MD Amer Zeidan, MBBS Released: December 23, 2021

Results from the phase III PANTHER trial evaluating pevonedistat + azacitidine vs azacitidine in higher-risk MDS/CMML or low-blast AML from ASH 2021, as reported by Clinical Care Options (CCO)

Pelabresib (CPI-0610) monotherapy active in patients with myelofibrosis in the ongoing phase II MANIFEST trial presented at ASH 2021 and reported by Clinical Care Options (CCO)

Rusfertide substantially reduced need for phlebotomy and improved hematocrit control in patients with phlebotomy-dependent polycythemia vera in a study presented at ASH 2021 and reported by Clinical Care Options (CCO)